Industry
Biotechnology
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Loading...
Open
2.18
Mkt cap
149M
Volume
443K
High
2.32
P/E Ratio
-6.71
52-wk high
6.35
Low
2.15
Div yield
N/A
52-wk low
2.00
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 10:27 am
Portfolio Pulse from Benzinga Newsdesk
October 18, 2024 | 12:18 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 4:29 pm
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 10:59 am
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 8:52 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 12:20 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 1:22 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 3:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 1:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 10:09 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.